Search

Innate Pharma SA

Closed

1.528 1.6

Overview

Share price change

24h

Current

Min

1.456

Max

1.54

Key metrics

By Trading Economics

Income

-28M

Sales

-2.1M

EPS

-0.12

Profit margin

1,342.644

Employees

164

EBITDA

-31M

Dividends

By Acuity

Next Earnings

16 wrz 2026

Market Stats

By TradingEconomics

Market Cap

144M

Previous open

-0.07

Previous close

1.528

Innate Pharma SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 sie 2026, 23:56 UTC

Baidu Inc. shares are roughly flat in after-market trading, remaining near unchanged since Tuesday's close and positioned around the midpoint of its one-month range.

4 sie 2026, 23:56 UTC

Ziff Davis Inc shares are lower during after-market hours, with no specific news identified to explain the movement. The stock fluctuated earlier in the session.

4 sie 2026, 23:56 UTC

Centene Corp shares are higher in after-market hours, continuing a recent upward trend amid positive market sentiment following a narrowing U.S. trade deficit.

4 sie 2026, 23:56 UTC

Insulet Corp shares are lower in after-market hours, showing little change since Tuesday's close amid a lack of specific company news.

4 sie 2026, 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

4 sie 2026, 23:56 UTC

Xcel Energy shares advanced in after-market trading, reaching a high of 0.60% above Tuesday's close, though still below the 20-day moving average.

4 sie 2026, 23:56 UTC

Nasdaq Inc. shares showed routine trading activity during after-market hours, remaining roughly flat since Tuesday's close and positioned above its 20-day moving average.

4 sie 2026, 23:56 UTC

Correlated Moves
ETF Constituents
Macro News

The iShares U.S. Aerospace & Defense ETF is trading higher in after-market hours, supported by positive earnings from technology stocks and geopolitical developments.

4 sie 2026, 23:56 UTC

Darling Ingredients Inc shares are higher in after-market trading, rebounding from earlier session lows. No specific news was identified to explain the movement.

4 sie 2026, 23:56 UTC

ETF Constituents

The Consumer Staples Select Sector SPDR Fund traded near unchanged in after-market hours, supported by positive contributions from Walmart, Costco, and PepsiCo.

4 sie 2026, 23:56 UTC

Public Service Enterprise Group Inc shares are modestly higher in after-market hours. No specific company news was identified to explain the movement.

4 sie 2026, 23:56 UTC

TE Connectivity Ltd. shares are lower in after-market trading, retracing from earlier gains. The stock remains above its 20-day moving average.

4 sie 2026, 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares declined in after-market trading, moving lower since Tuesday's close. The stock remains above its 20-day moving average.

4 sie 2026, 23:56 UTC

TAL Education Group shares are higher in after-market hours, recovering slightly after three consecutive sessions of decline and remaining above the 20-day moving average.

4 sie 2026, 23:56 UTC

Packaging Corp of America shares were roughly flat in after-market hours, remaining above their 20-day moving average following three consecutive higher sessions.

4 sie 2026, 23:56 UTC

Regions Financial Corp shares are higher in after-market hours, continuing a trend of strength following four consecutive sessions of gains.

4 sie 2026, 23:56 UTC

Fuelcell Energy Inc shares are lower in after-market trading, with no specific company news identified to explain the decline following Tuesday's close.

4 sie 2026, 23:56 UTC

MACOM Technology Solutions Holdings Inc. shares are lower in after-market trading, reflecting routine fluctuations and positioning below the 20-day moving average.

4 sie 2026, 23:56 UTC

News

Starbucks Corp raised its full-year EPS guidance to approximately $2.60, reflecting strong U.S. same-store sales growth. Shares are gaining in after-market trading.

4 sie 2026, 23:56 UTC

MKS Instruments Inc shares are lower in after-market hours, reflecting notable weakness as they remain significantly below their 20-day moving average.

4 sie 2026, 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

4 sie 2026, 23:56 UTC

News

Alphabet Inc's market valuation is approximately $4.6 trillion, bolstered by strong second-quarter results. Shares traded higher in after-market hours, reflecting positive sentiment.

4 sie 2026, 23:56 UTC

The US 10Y Treasury Bond Index is trading roughly flat. The U.S. trade deficit narrowed to $73.3 billion in June from $77.6 billion in May.

4 sie 2026, 23:56 UTC

Whirlpool Corp shares are trading lower in after-market hours, with no specific news identified to explain the movement. They remain near the upper end of their one-month range.

4 sie 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, following a volatile session with no specific news identified to explain the movement.

4 sie 2026, 23:56 UTC

News

Ameresco Inc reported second-quarter revenue of $515.5 million, a 9% increase year-over-year. Shares are trading higher in after-market hours following the results.

4 sie 2026, 23:56 UTC

News

Advanced Energy Industries reported record Q2 revenue of $574.1 million, leading to shares trading higher in after-market hours.

4 sie 2026, 23:56 UTC

Ultra Clean Holdings Inc. shares are higher in after-market trading, despite no specific company news identified. The broader market reflects a narrowing U.S. trade deficit.

4 sie 2026, 23:52 UTC

Correlated Moves

Teradyne Inc. shares gained in after-market trading, reflecting positive sentiment in U.S. markets amid easing inflation concerns related to oil supply negotiations.

4 sie 2026, 23:52 UTC

Brazil's upcoming inflation report on August 11, 2026, is poised to influence central bank policy amid rising energy prices and declining manufacturing activity.

Peer Comparison

Price change

Innate Pharma SA Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
help-icon Live chat